Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
CompletedNCT03299556
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a proof of concept study to measure the effect of Wearable Health Technology (WHT), including the Apple Watch, iPhone, Pain App and Provider Dashboards on important clinical outcomes in patients treated for chronic pain. WHT will be tested in a group of chronic pain patients treated at a specialty pain clinic, the Geisinger Multidisciplinary Pain Program (MPP). Primary and secondary outcomes include pain, physical function, depression, pain medicine use, amount of sleep, activity levels, healthcare resource utilization and cost. The WHT will collect self-reported data on pain, pain management therapies, and medication utilization, and passively collected data on subject activity levels and sleep. Additional data will be collected on device utilization by patients and health care professionals.
Study details
- Official title
- Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
- Conditions
- Interventions
- Other: WHT
- Sponsor
- Purdue Pharma LP
- Collaborators
- Geisinger Clinic
- Start date
- 2017-10-05
- Primary completion
- 2019-11-30
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Admission to the MPP * Completion of the 3-day MPP training * Ability to understand and complete the informed consent form prior to the initiation of any study procedures * Adequate motor skills needed to utilize WHT * Willingness to utilize personal electronic devices and WHT, as expressed and documented during the informed consenting process * Ability to understand spoken and written English Exclusion Criteria: * Cancer diagnosis, AIDS, end-stage liver disease or end-stage renal disease * Hospitalization \>30 days during the 12 months prior to Index Date * Nursing home or hospice care during the 12 months prior to Index Date * Presence of an EHR Diagnosis description "OPT-OUT CENTER RESEARCH" which indicates the subject has opted out of (i.e., does not wish to be included in) any Geisinger retrospective research * Has a terminated Medicine Use Agreement on their Problem List, indicator for substance abuse/dependence
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03299556